David Nanus is an Oncology physician affiliated with NewYork–Presbyterian Hospital. OpenAlex indexes 817 publications with 30,171 citations (h-index 75); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
520 E 70th St
Starr 341
New York, NY 100219800
Telephone
646-962-2072Provider last certified this registry record 6 Jul 2023.
Clinical trials
- Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Weill Medical College of Cornell University
- Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer
Sponsor: Weill Medical College of Cornell University
- Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Sponsor: Weill Medical College of Cornell University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year20251 payment
- PFIZER INC.Program year20251 payment
- PFIZER INC.Program year20243 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
43.9%Androgen Receptor Inhibitor43.9%Bicalutamide52%Xtandi48%Part D<11 patientsMetabolism & gastrointestinal
36.8%Corticosteroid36.8%Prednisone100%Part D<11 patientsGenitourinary & hormones
19.3%alpha-Adrenergic Blocker19.3%Tamsulosin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 1992–2007 per NIH RePORTER. The latest:
- PHASE II TRIAL OF 177LU-J591 IN METASTATIC, ANDROGEN-INDEPENDENT PROSTATE CANCER
Weill Medical Coll of Cornell Univ
FY2007$3,510M01RR000047 - PHASE I TRIAL OF ATRA-IV & DEPAKOTE IN PTS W/ADVANCED SOLID TUMOR MALIGNANCIES
Weill Medical Coll of Cornell Univ
FY2006$8,914M01RR000047 - Modulation of retinoic acid action in renal cancer
Weill Medical College of Cornell Univ
FY2005$381,213R01CA092542
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Lawrence Honig, MD, PhD
NewYork–Presbyterian Hospital
Nasser Altorki, MD
NewYork–Presbyterian Hospital
Michael Niederman, MD
NewYork–Presbyterian Hospital
Shunichi Homma, MD
NewYork–Presbyterian Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”